Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Operating Expenses: 2023-2025

  • Allogene Therapeutics' Other Operating Expenses fell 52.25% to $2.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $31.3 million, marking a year-over-year change of. This contributed to the annual value of $15.7 million for FY2024, which is 18.66% up from last year.
  • As of Q2 2025, Allogene Therapeutics' Other Operating Expenses stood at $2.4 million, which was down 77.80% from $10.7 million recorded in Q3 2024.
  • In the past 5 years, Allogene Therapeutics' Other Operating Expenses registered a high of $13.2 million during Q4 2023, and its lowest value of $2.4 million during Q2 2025.
  • Moreover, its 3-year median value for Other Operating Expenses was $7.9 million (2024), whereas its average is $7.8 million.
  • Data for Allogene Therapeutics' Other Operating Expenses shows a maximum YoY plummeted of 52.25% (in 2025) over the last 5 years.
  • Allogene Therapeutics' Other Operating Expenses (Quarterly) stood at $13.2 million in 2023, then reached $10.7 million in 2024, then crashed by 52.25% to $2.4 million in 2025.
  • Its Other Operating Expenses stands at $2.4 million for Q2 2025, versus $10.7 million for Q3 2024 and $5.0 million for Q2 2024.